ArticleEpidemiology and psychiatric sciences2018
Symptom rating scales for schizophrenia and other primary psychotic disorders in ICD-11.
Article in Epidemiology and psychiatric sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Antipsychotic-like effects of TAAR1 agonists and D2 receptor blockers are mediated through distinct modulation of striatal neuronal dynamics.Molecular psychiatry · 2026Article
- Article
- Changes of psychological and biological stress parameters in individuals with schizophrenia spectrum disorders participating in a mindfulness-based group therapy.Schizophrenia (Heidelberg, Germany) · 2026Article
- The influence of group physical activity on oxytocin, empathy, affect, and stress in individuals with schizophrenia spectrum disorders in a single-arm, pilot and exploratory study.Discover mental health · 2026Article
- Exploring the intricate interplay between metabolic abnormalities and multidimensional cognitive impairment in stable schizophrenia patients.Translational psychiatry · 2026Observational
- Uncertainty modeling in multimodal speech analysis across the psychosis spectrum.NPJ digital medicine · 2026Article
- TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Analysis of risk factors for hospital-acquired pneumonia in schizophrenia.Frontiers in psychiatry · 2024Review
- Dynamics of Clinical Manifestations and Social Functioning in Schizophrenia: A Non-interventional Observational Study of Paliperidone Palmitat Dosage Forms.Consortium psychiatricum · 2024Article
- Article
- An examination of plasma autoantibodies against voltage gated calcium channels in schizophrenia.Brain, behavior, & immunity - health · 2023Article
- Sex differences in factors influencing hospital-acquired pneumonia in schizophrenia patients receiving modified electroconvulsive therapy.Frontiers in psychiatry · 2023Article
- Brief Clinical Assessment Scale for Schizophrenia (BCASS): Development, Validity, and Reliability Study.Noro psikiyatri arsivi · 2022Article
- Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.International journal of molecular sciences · 2021Review
- Effects of High-Frequency rTMS on Negative Symptoms and Cognitive Function in Hospitalized Patients With Chronic Schizophrenia: A Double-Blind, Sham-Controlled Pilot Trial.Frontiers in psychiatry · 2021Article
- ICD-11 chapter on mental and behavioural disorders: heralding new ways of seeing old problems.Epidemiology and psychiatric sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The subtype system for categorising presentations of schizophrenia will be removed from International Classification of Diseases 11th Revision. In its place will be a system for rating six domains of psychotic disorder pathology: positive symptoms, negative symptoms, depressive symptoms, manic symptoms, psychomotor symptoms and cognitive symptoms. This paper outlines the rationale and description of the proposed symptom rating scale, including current controversies. In particular, the scale could adopt either a 4-point severity rating or a 2-point presence/absence rating. The 4-point scale has the advantage of gathering more information, but potentially at the cost of reliability. The paper concludes by describing the field testing process for evaluating the proposed scale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.